HER-2 negative

News alerts, weekly reports and conference planners

Entrez ID:

2064

Related biomarkers:

‹

›

HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	pembrolizumab Sensitive: A2 - Guideline NCCN - 6 days (New A2) pembrolizumab Sensitive : A2 NCCN - 6d	pembrolizumab Sensitive: A2 - Guideline NCCN - 6 days pembrolizumab Sensitive : A2 NCCN - 6 days - (New A2)
HER-2 negative	Gastroesophageal Junction Adenocarcinoma	HER-2 negative	Gastroesophageal Junction Adenocarcinoma	camrelizumab + rivoceranib Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks (New C3) camrelizumab + rivoceranib Sensitive : C2 ASCO-GI 2023 - 2wk	camrelizumab + rivoceranib Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks camrelizumab + rivoceranib Sensitive : C2 ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 negative	Gastric Cancer	HER-2 negative	Gastric Cancer	camrelizumab + rivoceranib Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks (New C3) camrelizumab + rivoceranib Sensitive : C2 ASCO-GI 2023 - 2wk	camrelizumab + rivoceranib Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks camrelizumab + rivoceranib Sensitive : C2 ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 negative	Gastroesophageal Junction Adenocarcinoma	HER-2 negative	Gastroesophageal Junction Adenocarcinoma	anlotinib + APL-502 Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) anlotinib + APL-502 Sensitive : C3 ASCO-GI 2023 - 2wk	anlotinib + APL-502 Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks anlotinib + APL-502 Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 negative	Gastric Cancer	HER-2 negative	Gastric Cancer	anlotinib + APL-502 Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) anlotinib + APL-502 Sensitive : C3 ASCO-GI 2023 - 2wk	anlotinib + APL-502 Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks anlotinib + APL-502 Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 negative	Gastric Cancer	HER-2 negative	Gastric Cancer	cisplatin + capecitabine Sensitive: A2 - Guideline cisplatin + capecitabine Sensitive : A2	cisplatin + capecitabine Sensitive: A2 - Guideline cisplatin + capecitabine Sensitive : A2
HER-2 negative	Gastroesophageal Junction Adenocarcinoma	HER-2 negative	Gastroesophageal Junction Adenocarcinoma	cisplatin + capecitabine Sensitive: A2 - Guideline cisplatin + capecitabine Sensitive : A2	cisplatin + capecitabine Sensitive: A2 - Guideline cisplatin + capecitabine Sensitive : A2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	CaT Sensitive: A2 - Guideline CaT Sensitive : A2	CaT Sensitive: A2 - Guideline CaT Sensitive : A2
HER-2 negative	Gastroesophageal Junction Adenocarcinoma	HER-2 negative	Gastroesophageal Junction Adenocarcinoma	CAPOX Sensitive: A2 - Guideline CAPOX Sensitive : A2	CAPOX Sensitive: A2 - Guideline CAPOX Sensitive : A2
HER-2 negative	Gastroesophageal Junction Adenocarcinoma	HER-2 negative	Gastroesophageal Junction Adenocarcinoma	5-fluorouracil + oxaliplatin Sensitive: A2 - Guideline 5-fluorouracil + oxaliplatin Sensitive : A2	5-fluorouracil + oxaliplatin Sensitive: A2 - Guideline 5-fluorouracil + oxaliplatin Sensitive : A2
HER-2 negative	Gastroesophageal Junction Adenocarcinoma	HER-2 negative	Gastroesophageal Junction Adenocarcinoma	FP Sensitive: A2 - Guideline FP Sensitive : A2	FP Sensitive: A2 - Guideline FP Sensitive : A2
HER-2 negative	Gastric Cancer	HER-2 negative	Gastric Cancer	cisplatin + 5-fluorouracil Sensitive: A2 - Guideline cisplatin + 5-fluorouracil Sensitive : A2	cisplatin + 5-fluorouracil Sensitive: A2 - Guideline cisplatin + 5-fluorouracil Sensitive : A2
HER-2 negative	Gastric Cancer	HER-2 negative	Gastric Cancer	CAPOX Sensitive: A2 - Guideline CAPOX Sensitive : A2	CAPOX Sensitive: A2 - Guideline CAPOX Sensitive : A2
HER-2 negative	Gastric Cancer	HER-2 negative	Gastric Cancer	5-fluorouracil + oxaliplatin Sensitive: A2 - Guideline 5-fluorouracil + oxaliplatin Sensitive : A2	5-fluorouracil + oxaliplatin Sensitive: A2 - Guideline 5-fluorouracil + oxaliplatin Sensitive : A2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	eribulin mesylate Sensitive: A2 - Guideline eribulin mesylate Sensitive : A2	eribulin mesylate Sensitive: A2 - Guideline eribulin mesylate Sensitive : A2
HER-2 negative	Gastric Cancer	HER-2 negative	Gastric Cancer	nivolumab Sensitive: A2 - Guideline nivolumab Sensitive : A2	nivolumab Sensitive: A2 - Guideline nivolumab Sensitive : A2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	ribociclib Sensitive: A2 - Guideline ribociclib Sensitive : A2	ribociclib Sensitive: A2 - Guideline ribociclib Sensitive : A2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	docetaxel Sensitive: A2 - Guideline docetaxel Sensitive : A2	docetaxel Sensitive: A2 - Guideline docetaxel Sensitive : A2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	paclitaxel Sensitive: A2 - Guideline paclitaxel Sensitive : A2	paclitaxel Sensitive: A2 - Guideline paclitaxel Sensitive : A2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	bevacizumab Sensitive: A2 - Guideline bevacizumab Sensitive : A2	bevacizumab Sensitive: A2 - Guideline bevacizumab Sensitive : A2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	albumin-bound paclitaxel Sensitive: A2 - Guideline albumin-bound paclitaxel Sensitive : A2	albumin-bound paclitaxel Sensitive: A2 - Guideline albumin-bound paclitaxel Sensitive : A2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	ixabepilone Sensitive: A2 - Guideline ixabepilone Sensitive : A2	ixabepilone Sensitive: A2 - Guideline ixabepilone Sensitive : A2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	capecitabine Sensitive: A2 - Guideline capecitabine Sensitive : A2	capecitabine Sensitive: A2 - Guideline capecitabine Sensitive : A2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	gemcitabine Sensitive: A2 - Guideline gemcitabine Sensitive : A2	gemcitabine Sensitive: A2 - Guideline gemcitabine Sensitive : A2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	vinorelbine tartrate Sensitive: A2 - Guideline vinorelbine tartrate Sensitive : A2	vinorelbine tartrate Sensitive: A2 - Guideline vinorelbine tartrate Sensitive : A2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	letrozole Sensitive: A2 - Guideline letrozole Sensitive : A2	letrozole Sensitive: A2 - Guideline letrozole Sensitive : A2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	docetaxel + capecitabine Sensitive: A2 - Guideline docetaxel + capecitabine Sensitive : A2	docetaxel + capecitabine Sensitive: A2 - Guideline docetaxel + capecitabine Sensitive : A2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	tamoxifen Sensitive: A2 - Guideline tamoxifen Sensitive : A2	tamoxifen Sensitive: A2 - Guideline tamoxifen Sensitive : A2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	carboplatin + albumin-bound paclitaxel Sensitive: A2 - Guideline carboplatin + albumin-bound paclitaxel Sensitive : A2	carboplatin + albumin-bound paclitaxel Sensitive: A2 - Guideline carboplatin + albumin-bound paclitaxel Sensitive : A2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	everolimus Sensitive: A2 - Guideline everolimus Sensitive : A2	everolimus Sensitive: A2 - Guideline everolimus Sensitive : A2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	TC Sensitive: A2 - Guideline TC Sensitive : A2	TC Sensitive: A2 - Guideline TC Sensitive : A2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	fulvestrant Sensitive: A2 - Guideline fulvestrant Sensitive : A2	fulvestrant Sensitive: A2 - Guideline fulvestrant Sensitive : A2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	fulvestrant + anastrozole Sensitive: A2 - Guideline fulvestrant + anastrozole Sensitive : A2	fulvestrant + anastrozole Sensitive: A2 - Guideline fulvestrant + anastrozole Sensitive : A2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	fulvestrant + letrozole Sensitive: A2 - Guideline fulvestrant + letrozole Sensitive : A2	fulvestrant + letrozole Sensitive: A2 - Guideline fulvestrant + letrozole Sensitive : A2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	palbociclib Sensitive: A2 - Guideline palbociclib Sensitive : A2	palbociclib Sensitive: A2 - Guideline palbociclib Sensitive : A2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	abemaciclib Sensitive: A2 - Guideline abemaciclib Sensitive : A2	abemaciclib Sensitive: A2 - Guideline abemaciclib Sensitive : A2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	exemestane Sensitive: A2 - Guideline exemestane Sensitive : A2	exemestane Sensitive: A2 - Guideline exemestane Sensitive : A2

HER-2 negative

Associations